Observation of contrast enhancement in the cochlear fluid space of healthy subjects using a 3D-FLAIR sequence at 3 Tesla
Observation of contrast enhancement in the cochlear fluid space of healthy subjects using a 3D-FLAIR sequence at 3 Tesla
复制标题
DOI：
10.1007/s00330-005-0046-8
复制
发表时间：
2006-03-01
影响因子：
5.9
通讯作者：
Takizawa, O
中科院分区：
文献类型：
--
作者：
Naganawa, S;Komada, T;Takizawa, O
在动物实验中，已报道使用1.25 mmol/kg的Gd-DTPA增强耳蜗淋巴周围，允许在诊断梅尼埃病时单独观察淋巴周围和内淋巴。本研究的目的有三个方面：(1)确定健康受试者静脉注射0.1 mmol/kg Gd-DTPA后使用3D-FLAIR（液体衰减反转恢复）检测耳蜗液增强的最佳时机；(2)在多名健康受试者中检验增强的可靠性；(3)探讨内淋巴间隙和外淋巴间隙是否可以视觉区分。在两名健康受试者中，分别在注射前、注射后、注射后2 h、4 h和6 h获得3D-FLAIR图像。另外3名健康受试者在注射前和注射后4小时进行扫描。在最初两名受试者的所有四只耳朵中，耳蜗液在注射后4小时被发现增强最强烈。另外3例均在注射后4 h耳蜗液信号增高。然而，淋巴内液和淋巴周围液的视觉分化无法实现。使用3D-FLAIR和Gd-DTPA，即使注射单剂量造影剂，也可以在健康人耳中观察到耳蜗液增强。
In animals, the enhancement of perilymph in the cochlea has been reported using 1.25 mmol/kg of Gd-DTPA, allowing the separate visualisation of perilymph and endolymph for the diagnosis of Meniere's disease. The purpose of this study was three-fold: (1) to determine the optimal timing for detecting cochlear fluid enhancement using 3D-FLAIR (fluid-attenuated inversion recovery) after intravenous administration of 0.1 mmol/kg of Gd-DTPA in healthy human subjects; (2) to examine the reliability of enhancement in multiple healthy subjects; and (3) to investigate whether endolymph and perilymph space can be visually discriminated. In two healthy subjects, 3D-FLAIR images were obtained before, immediately after and 2 h, 4 h and 6 h after the injection. Three more healthy subjects were scanned before and 4 h after the injection. In all four ears of the initial two subjects, cochlear fluid was found to be most intensely enhanced 4 h after the injection. In all of the additional three subjects, the cochlear fluid signal had increased after 4 h from injection. However, visual differentiation of endolymph and perilymph fluid could not be achieved. Using 3D-FLAIR and Gd-DTPA, cochlear fluid enhancement can be observed in healthy human ears, even with a single dose of contrast-medium injection.